HepaCheC® is an ELISA-based assay that detects aberrant and cancer-specific glycosylation on alpha-1-acid glycoprotein (AGP). The method is based on a patented fucose-binding protein, Mono-F, developed from the lectin Aleuria aurantia (1-3). Mono-F has a high binding specificity for core and multivalent fucosylation. This type of glycosylation has been implicated as a specific biomarker for HCC (4).
AGP (also known as orosomucoid), is an acute phase plasma glycoprotein primarily synthesized in the liver. Mono-F recognizes HCC-specific glycosylation independent of the protein but detection on AGP was chosen due to 1) the high concentration of AGP in serum from normal individuals (0.8-1.2 g/L; a 1000 times higher than AFP), 2) lack of reported genetic deficiencies and 3) lack of multimeric complex formation. HepaCheC® utilizes AGP's high abundancy and extensive glycosylation and detects fucosylated AGP bound to Mono-F by use of a specifically designed primary antibody (in-house invention). The immunoassay is then completed by using a commercially available product; horseradish peroxidase-conjugated goat anti-rabbit IgG.
1. Olausson et al, Glycoconj J, 2008;25(8):753-62.
2. Olausson et al, Glycobiology, 2011;21(1):34-44.
3. Bergström et al, J Chromatogr B Analyt Technol BiomedLife Sci, 2012;15:885-886:66-72.
4. Tanabe et al, J Proteome Res, 2016;15:2935-2944.